Details
Nuclear Physics 3
Radiopharmaceuticals Used in Nuclear MedicineISTE Invoiced 1. Aufl.
|
142,99 € |
|
| Verlag: | Wiley |
| Format: | |
| Veröffentl.: | 03.07.2024 |
| ISBN/EAN: | 9781394306367 |
| Sprache: | englisch |
| Anzahl Seiten: | 288 |
DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.
Beschreibungen
<p><i>Nuclear Physics 3</i> presents the applications of various radioisotopes in nuclear medicine, with a focus on radiological imaging methods such as X-rays, γ scintigraphy – PET – MRI and ultrasound, which do not exploit the properties of radiopharmaceuticals. The book then presents the physicochemical and pharmacological properties of radiopharmaceuticals labeled with 99mTc, 201Tl, 18mKr, 18F and the radioisotopes 123I, 125I and 131I used in nuclear medicine.</p> <p>The production chains for the radiotracers studied, as well as their main emissions, are then described in detail, followed by a study of the clearance mechanisms of the radiopharmaceuticals under consideration. Finally, the book describes the principles of myocardial, pulmonary, bone, thyroid, renal and gastric emptying scans using the properties of the radiotracers studied, as well as the principles of prostate brachytherapy using iodine-125 implants and prostate chemotherapy.</p>
<p>Preface ix</p> <p><b>Chapter 1. Radiological Imaging 1</b></p> <p>1.1. Radiological imaging and nuclear medicine imaging 3</p> <p>1.2. X-ray imaging 9</p> <p>1.3. Nuclear magnetic resonance (NMR) 18</p> <p>1.4. Magnetic resonance imaging (MRI) 35</p> <p>1.5. Ultrasound imaging 71</p> <p><b>Chapter 2. Technetized Radiopharmaceuticals and Radiothallium-201 used in Nuclear Medicine 77</b></p> <p>2.1. Metastable technetium-99 and thallium-201 radiotracers 79</p> <p>2.2. Metastable technetium-99 radiotracers 87</p> <p>2.3. Technetium-labeled radiopharmaceuticals used in myocardial scintigraphy 91</p> <p>2.4. Radiopharmaceuticals labeled with metastable technetium-99 used in lung scintigraphy 97</p> <p>2.5. Radiopharmaceuticals used in brain scintigraphy 101</p> <p>2.6. Production, use and dosimetry of radiothallium-201 107</p> <p>2.7. Myocardial scintigraphy 112</p> <p>2.8. Radiopharmaceuticals used in bone scintigraphy 122</p> <p>2.9. Radiopharmaceuticals used in renal scintigraphy 127</p> <p>2.10. Radiopharmaceuticals used in digestive scintigraphy 137</p> <p><b>Chapter 3. Radioisotopes Fluorine-18, Metastable Krypton-81 and Iodine-123, 125 and 131 used in Nuclear Medicine 139</b></p> <p>3.1. Properties and uses of the radiotracer 18FDG 140</p> <p>3.2. Properties of the 81mKr radiotracer, dosimetry 154</p> <p>3.3. Lung scintigraphy examination 157</p> <p>3.4. Radiopharmaceuticals used in thyroid scintigraphy 161</p> <p>3.5. General information on aerosols 177</p> <p>3.6. Prostate disorders 183</p> <p>3.7. Principle of prostate brachytherapy using an iodine-125 implant 195</p> <p>3.8. Appendices 203</p> <p>References 231</p> <p>Index 255</p>
<b>Ibrahima Sakho</b> is a teacher-researcher-writer at Iba Der Thiam University, Senegal. He has taught nuclear physics for more than 25 years. His main research interests include resonant photoionisation and assessing the risks of radiation-induced cancers due to off-field doses in external radiotherapy.
Diese Produkte könnten Sie auch interessieren:
